04:10 AM EDT, 04/02/2024 (MT Newswires) -- Hutchmed ( HCM ) and Innovent Biologics said Tuesday a new drug application for the sintilimab-fruquintinib combination for the treatment of advanced endometrial cancer has been accepted by the China National Medical Products Administration with a priority review status.

The filing was supported by data from a phase 2 trial which evaluated the drug combination in patients who experienced disease recurrence, disease progression or intolerable toxicity with treatment on platinum-based doublet chemotherapy, the companies said.